{"entity":{"id":"hdp-102","kind":"drug","name":"HDP-102","aka":["CD37-ATAC"],"tldr":"HDP-102 is an experimental antibody-drug conjugate with an amanitin payload from Heidelberg Pharma, in phase 1 trials for non-Hodgkin lymphoma; development is paused.","summary":"HDP-102 (CD37-ATAC) is an antibody-drug conjugate with an amanitin payload (ATAC) from Heidelberg Pharma. An amanitin conjugate targeting CD37, which is overexpressed on B-cell lymphoma cells. Its furthest stage is phase 1, for non-Hodgkin lymphoma. No clinical trial naming it is registered on ClinicalTrials.gov. First patient dosed end of May 2025; recruitment paused after the first cohort after the September 2025 strategic review, all trial centres closed; partner sought (company page). It has not been shown to work in people.","status":"phase-1","asOf":"2026-11-03","links":[{"label":"Heidelberg Pharma: heidelberg-pharma.com","url":"https://heidelberg-pharma.com/en/research-development/atac-r-projects"},{"label":"Heidelberg Pharma: heidelberg-pharma.com","url":"https://heidelberg-pharma.com/en/research-development/atac-r-projects"}],"tags":["pipeline"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["heidelberg-pharma"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"HDP-102","modality":"Antibody-drug conjugate with an amanitin payload (ATAC)","mechanism":"An amanitin conjugate targeting CD37, which is overexpressed on B-cell lymphoma cells.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/hdp-102/","neighbours":{"company":[{"id":"heidelberg-pharma","kind":"company","name":"Heidelberg Pharma","route":"/companies/heidelberg-pharma/"}]}}